CA2112619A1 - Method for improving the biocompatibility of solid surfaces - Google Patents

Method for improving the biocompatibility of solid surfaces

Info

Publication number
CA2112619A1
CA2112619A1 CA002112619A CA2112619A CA2112619A1 CA 2112619 A1 CA2112619 A1 CA 2112619A1 CA 002112619 A CA002112619 A CA 002112619A CA 2112619 A CA2112619 A CA 2112619A CA 2112619 A1 CA2112619 A1 CA 2112619A1
Authority
CA
Canada
Prior art keywords
biomolecule
carbodiimide
solid surface
aminated
carboxyl groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002112619A
Other languages
French (fr)
Inventor
Michel Verhoeven
Patrick Cahalan
Linda Cahalan
Marc Hendriks
Benedicte Foache
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Publication of CA2112619A1 publication Critical patent/CA2112619A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005Use of materials characterised by their function or physical properties
    • A61L33/0011Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0029Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using an intermediate layer of polymer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005Use of materials characterised by their function or physical properties
    • A61L33/0011Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0041Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005Use of materials characterised by their function or physical properties
    • A61L33/0047Enzymes, e.g. urokinase, streptokinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0076Chemical modification of the substrate
    • A61L33/0088Chemical modification of the substrate by grafting of a monomer onto the substrate

Abstract

ABSTRACT

A method for attaching a biomolecule having a plurality of carboxyl groups to an aminated solid surface by reacting the biomolecule with a carbodiimide to effect an activation of the carboxyl groups of the biomolecule, reacting the carbodiimide activated biomolecule with the solid surface to covalently bind the biomolecule to the aminated solid surface, and then selectively restoring carboxyl groups to the biomolecule. The selective restoration of carboxyl groups can be carried out by mild hydrolysis and restores the functionality of the biomolecule. The method is "selective" since the bonds between the biomolecule and the aminated solid surface remain intact.

Description

-` p-5076 1 2~12~

MET~OD FOR INPROVING TH2 BIOCONPATIBILITY OF 80LID 8~RFACE~

BAC~GROUND OF ~ INVENTION
This invention relates to the enhancement of the biocompatibility of various surfaces by binding biomolecules containing carboxyl groups to aminated surfaces.
Medical devices which serve as substitute blood vessels, synthetic and intraocular lenses, electrodes, catheters and the like in and on the body or as extracorporeal devices intended to be connected to the body to assist in surgery or dialysis are well known. ~owever, the use of such biomaterials in medical devices can stimulate adverse body responses, including rapid thrombogenic action. Various plasma proteins play a role in initiating platel~t and fibrin deposition on plastic surfaces. These actions lead to vascular constriction to hinder blood flow, and the inflammatory reaction that follow~ can lead to the loss o~ function of the ~edical device.
A "biomaterial" may be defined as a material that is substantially insoluble in body fluids and that is designed and constructed to be placed in or onto the body or to contact fluid of the body. Ideally, a biomaterial will not induce undesirable reactions in the body such as blood clotting, tissue death, tumor formation, allergic reaction, foreign body reaction trejection) or inflammatory reaction;
will have the physical properties such as strength, elasticity, permeability and flexibility required to function for the intended purpose; can be purified, fabricated and sterilized easily; will substantially maintai~ its physical properties and function during the time that it remains implanted in or in contact with the body 2 21~19 As used herein, the solid surface of a biomaterial is characterized as "biocompatible" if it is capable of functioning or existing in contact with biological fluid and/or tissue of a living organism with a net beneficial effect on the living organism. Long term biocompatibility is desired for the purpose of reducing disturbance of the host organism. One approach to improved biocompatibility for biomaterials is to attach various ~biomolecules" such as growth factors, antimicrobial agents, antithrombogenic agents, and cell attachment proteins to the surface of the material.
A number of approaches have been suggested to attach such biomolecules. One such approach is set forth in U.S. Patent 4,521,564 to Solomon et al. in which an antithrombogenic agent is bonded to a solid polyurethane polymer support. A
polymeric amine such as polyvinyl amine, or a polyalkyleneamine is first covalently bonded to the ~
polyurethane substrate to provide an aminated surface. - -Then, an antithrombogenic agent is covalently bonded to the aminated substrate. The antithrombogenic agent is covalently bonded by first activating the antithrombogenic agent with a carbodiimide and then reacting it with the aminated surface of the substrate material. However, in Funahashi et al. "Preparation of Three Types of Heparin-Sepharose and ~heir Binding Activities to Thrombin and Antithrombin III" Analytical Biochemistry 126, 414-421 (1982), it was noted that by using the carbodiimide to bind an antithrombogenic agent (e.g. heparin) for an affinity chromatography support, that the carboxyl groups which provide the biomolecule with much of its bioactivity had reacted with the carbodiimide, thereby substantially reducing antithrombin III uptake.
It is therefore an object of the present invention to provide a biocompatible surface having active, covalently bonded biomolecules t~ereon.

. : ,. . .~ : . , . - :

. P-5076 3 2 ~ 1 9 It is also an object of the present invention to covalently attach biomolecules having carboxyl groups to aminated surfaces while retaining their bioactivity.
It is also an object of the present invention to preserve the bioactivity of biomolecules attached by the use of a carbodiimide.

8UMMARY OF T~B INV~NTION
We have discovered a method for attaching a biomolecule having a plurality of carboxyl groups to an aminated solid surface by reacting the biomolecule with a carbodiimide to effect an activation of the carboxyl groups of the biomolecule, reacting the carbodiimide activated biomolecule with the solid surface to covalently bind the biomolecule to the aminated solid surface, and then selectively restoring carboxyl groups to the biomolecule. The restoration of carboxyl groups can be accomplished by mild hydrolysis. While not wishing to be bound by theory, mild hydrolysis is believed to remove N-acyl urea groups formed as a side product from the reaction between biomolecule and carbodiimide from the functional carboxyl groups on the covalently bound biomolecule thereby restoring much of the functionality of the biomolecule without decoupling the biomolecule from the aminated solid surface.
This method can be used on aminated solid surfaces such as a polymeric substrate having amine functional groups grafted to it, for example, a substrate having a grafted amine functionalized acrylamide-containing polymer or a substrate having attached amine-terminated spacer molecules.
The k!iomolecule can be any biomolecule having a plurality of carboxy~l functional groups, and preferably one which is capable of providing a nonthrombogenic, blood-compatible surface such as heparin, streptokinase, tissue plasminogen activator (TPA) or urokinase or cell attachment proteins 4 21 ~ ~19 such as fibronectin or laminin. The carbodiimide used is preferably a water soluble carbodiimide of the structure RlN=C=NR2 where Rl can be an alkyl or cycloalkyl group and R2 can be an alkylamine or cycloalkylamine group such as 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride, or 1-cyclohexy1-3-(2-morpholinoethyl) carbodiimide.
The selective restoration of carboxyl groups can be carried out by mild hydrolysis by incubating the surface and biomolecule in the presence of water at a mild p~ for a period of time effective to restore the carboxyl groups.
Preferably, the reaction is carried out at a pH in the range -~
. of about 8 to 11, at a temperature in the range of about 0C
to 70C and for a period of time in the range of about 1 to 24 hours. For example, the surface with bonded biomolecule can be immersed in an aqueous 1 ~ solution of sodium bicarbonate (pH= 8.2) and heated to about 60C for 3 hours.
This process is "selective" since the bonds between the biomolecule and the aminated solid surface remain intact.

D~TAI~ED DE~CRIPTION OF TEB INVENTION
The solid surface that is rendered biocompatible in accordance with the invention desirably is of a synthetic or natural material that is insoluble in physiological fluids and which contains primary or secondary amine groups. The surface may be one or more surfaces of devices intended to function in contact with tissue and/or fluids of living organisms. The substrate for this aminated solid surface of the device may be any suitable metal such as polished titanium or stainless steel or a polymer such as polyurethane, polyvinylpyrrolidone, silicone elastomers, polyolefins such as polyethylene and polypropylene, polytetrafluoroethylene, polyvinyl chloride, polyesters, fluoropolymers, polyacrylates (including polymethacrylates);
minerals or ceramics such as hydroxyapatite; human or animal p-5076 5 2~

tissue such as bone, skin and teeth; organic materials such as wood, cellulose and compressed carbon; and other natural and synthetic materials such as glass, rubber, wood and the like. Examples of devices which may be provided with biocompatible surfaces in accordance with this invention include vascular graft tubing, dialysis tubing or membrane, blood oxygenator tubing or membrane, ultrafiltration membrane, intra aortic balloon, blood bag, catheter, suture, soft or hard tissue prosthesis, synthetic prosthesis, artificial organs, and lenses for the eye such as contact and intraocular lenses. While not wishing to be bound by theory, mild hydrolysis is believed to remove N-acyl urea groups from the functional carboxyl groups on the covalently bound biomolecule thereby restoring the functionality of the biomolecule without decoupling the biomolecule from the aminated solid surface.
If the substrate material does not have primary or secondary amines at its surface, such amine groups can be added to the surface by grafting or adsorbing an amine-containing chemical moiety onto the substrate material.
~rafting could be accomplished by covalent or ionic attachment. For example, polyvinyl amines or polyalkylimines can be covalently attached to polyurethane according to the method taught by U.S. Patent 4,521,S64 to Solomon et al. the disclosure of which is incorporated herein by reference. Or, for example, an aminosilane can be attached to the surface as set forth in U.S. Patent 5,053,048 to Pinchuk the disclosure of which is also incorporated herein by reference. Or, for example, a grafted acrylamide-containing polymer can be attached by radiatiop grafting (followed by amine functionalization) as set forth in U.S. Patent 3,826,678 to Hoffman et al. the disclosure of which is also incorporated herein by reference. A substrate having attached amine-terminated spacer molecules is preferred.

f - P-5076 2~ 2~19 A spacer molecule is a molecule or compound which is capable of attachment to a solid surface, is large enough to extend from the surface of said surface and is capable of immobilizing a biomolecule and/or biomolecules. The spacer insures that the active site of the biomolecule is held outward away from the support so as to contact the body fluid efficiently. The spacers are derived from organic molecules having at least two reactive functional groups generally situated at opposing ends of the molecule. Such groups serve as attachment vehicles capable of coupling the spacer to the solid surface and to the biomolecule. The reactive functional groups on the spacer may be the same or different however, they will provide amine functional groups along the solid surface which are available to form covalent bonds with the carboxyl functional groups extending from the biomolecule. Any known method for carrying out coupling reactions between the substrate material and the spacer molecule will suffice. Suitable examples of spacer~ which may be used in the present invention include, for example, C2 to C12 diamines, (e.g., 1,6-diaminohexane), ethylenediamine tetraacetic acid, 6-aminocaproic acid, aminopropyltriethoxy-silane and homocysteine thiolactone.
Polypeptides and proteins may also be used as spacers in the present invention and multiple coupling agents may be used on the same surface if desired.
The biomolecule can be any biomolecule having a plurality of carboxyl groups and, according to the present invention are attached to the surfaces of biomaterials to improve biocompatibility of the biomaterial. The biomolecule may be a growth factor such as endothelial cell growth -factor, epithelial cell growth factor, osteoblast growth factor,!fibroblast growth factor, platelet derived growth factor, neural growth factor, or angiogenin growth factor;
an antimicrobial agent such as lysozyme or penicillin; an antithrombogenic agent such as heparin, fractionated ~. . . .
~` .~ . . .
~` ~

P-5076 2112~19 heparins (e.g., on an AT-III column), heparan, heparan sulfate, chondroitin sulfate, modified dextran, albumin, streptokinase, tissue plasminogen activator (TPA) or urokinase; cell attachment proteins such as fibronectin or laminin; a thrombogenic agent such as collagen or a hydrophilic polymer such as hyaluronic acid, chitosan or methyl cellulose, and other proteins, carbohydrates and fatty acids.
The carbodiimide used is preferably a water soluble carbodiimide of the structure R1N=C=NR2 where R1 can be an alkyl or cycloalkyl group and R2 can be an alkylamine or cycloalkylamine group such as l-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride, or 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide. In the reaction bonding the biomolecule to the aminated solid surface, the first step is the reaction between a carboxyl group on the biomolecule and a carbodiimide molecule to form an 0-acylisourea ester. This can be carried out in aqueous solution and can be illustrated as follows:
O
HOOC- ~ + RlN=C=NR2 ~~~~~~~> R2HN-C-O-C- ~

(COOH)n NRl (O=C-ONC NRl)n (1) ` , This reaction is preferably undertaken in a cold solution (0-4C) at a pH of about 5 although a room temperature reaction is also acceptable. The biomolecule can be ~-pretreated with carbodiimide and then be brought into contact with the aminated support or the carbodiimide, biomolecule and aminated support can react concomitantly.
In the process, the carbodiimide reacts with the carboxyl gr~ups of the biomolecule (1) forming labile 0-acylisourea ;'. . .~. ~ ' ' :
.. : ~ '' ' ~ ~ '' ' ' ', , ' ' ' .. :

21.1 2~
p_so76 8 esters (2), susceptible to nucleophilic substitution.
Reaction with an amine leads to the formation of a suitable amide bond (2), resulting in effective immobilization of the biomolecule. Part of the remaining activated ester groups will undergo hydrolysis while the remaining ones will undergo an intramolecular rearrangement into relatively stable N-acyl urea groups, blocking the original carboxyl group and impairing bioactivity (3).

~ -NH2 + (1) -------~ ~-N~-C- ~ ~

(O=C-O-C=NRl) n (2) ~ 0 H20 + (2) ---->~ -NH-C- C ~

(O=C-OH) n-ll (O=C~ -C-NHR2) m o (3) The selective restoration of carboxyl groups by mild hydrolysis can be carried out by incubating the surface and biomolecule in the presence of a buffer for a period of time effective to restore the carboxyl groups. Preferably, the reaction is carried out at a pH in the range of about 8 to 11, at a temperature in the range of about 0C to 70C and for a period of time in the range of about 1 to 24 hours.
For example, the surface with bonded biomolecule can be immersed in an aqueous 1 M solution of sodium bicarbonate (pH= 8.2) and heated to about 60C for 3 hours. This process is "selective" for restoration of carboxyl group .. , , ,~,~,".: .~ - ........................... :' ':

.

-:-` P-5076 9 21126~ 9 functionality since the bonds made from the carboxyl groups between the biomolecule and the aminated solid surface remain intact. This reaction is as follows:
hydrolysis (3) ------------->_~-NH-C-o (COOH) n The following examples provide specific embodiments of the invention.

Polyurethane samples were provided with a grafted acrylamide surface. The samples were corona treated using a Sherman Treaters corona machine type HT3 with an input voltage of 650 volts and an output voltage of 13 KV. Sheet materials were given 6 to 12 passes at .25 KW with an electrode distance of 5 mm for each side. The treated sheets were placed in a 40 weight % solution of acrylamide, with stlrring, to which 1.75 ml. of a ceric ion solution (made by mixing 13.7 grams of ceric ammonium nitrate and 15.75 grams of fuming nitric acid with water to an aqueous solution volume of 250 ml.) was added per 100 grams of acrylamide solution. The test samples were then allowed to -~
react with the monomer solution for one hour at room temperature. The test samples were then removed from the monomer solution and thoroughly rinsed with deionized water.
The test samples were then incubated in water overnight at 60C to remove loosely bound polymer chains. The samples were then immersed in a 0.2M carbonate buffer pH=10.5 at 60C to introduce carboxylic acid groups in the grafted gel.
Subsequently, ethylene diamine was coupled to these groups by incubating the samples in a buffer solution containing 0.5M ethylene diamine~2HCl and 0.5M
4-morphyleneethanesulPonic acid, brought to pH=5Ø Water soluble carbodiimide was added up to a concentration of 0.lM

~ P-5076 10 21i2 ~l~

and amination was conducted for 1 hour at room temperature.
Test samples were then thoroughly rinsed in 0.2M acetate buffer pH=4.6, lM NaCl and copious amounts of water.

Aminated polyurethane samples made substantially as set forth in Example 1 were provided with covalently attached heparin by carbodiimide attachment. Covalent attachment was comparatively tested at both room temperatures and under cold conditions (ice bath). The test samples were immersed in a solution of 5 mg heparin (from porcine intestinal mucosa) per ml of buffer solution (0.5M 4-' morpholineethanesulfonic acid pH=5.0). Water soluble carbodiimide (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride was added to a concentration of 0.01 M. Test samples were stirred in the solution and reacted for 6 hours. The solution was then decanted and the samples were thoroughly rinsed with deionized water, 1 M NaCl, 1 M
NaHC03, and, again, deionized water. One group of test samples was immersed in 1 M NaHC03 for 3 hours at 60C
followed by extensive rinsing with deionized water. All samples were then stored in 0.2 M phosphate (pH=6.8) until bioactivity testing. Bioactivity testing was then conducted by determining the extent to which thrombin was deactivated by contact with the surface after incubation of the surface with antithrombin III. Results are shown in Table 1 and expressed in amounts of thrombin activated per unit of ~-surface.

A . . ' ' p 5076 11 2~2~1.......... i Table 1 Sample Bioactivity (NIH units thrombin/cm2) No hydrolysis, RT reaction 0.40 No hydrolysis, Cold reaction 0.48 Hydrolysis, RT reaction 0.935 Hydrolysis, Cold reaction 1.126 Fibronectin was attached to an acrylamide-grafted lo substrate according to the present invention according to the following method.
A hydrolyzed acrylamid-grafted test sample is inserted into a 0.5M M morpholineethanesulfonic acid (MES) buffered solution of 0.5M ethylene diamine pH=5Ø To this solution, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) is added until a final concentration of 0.005 M is achieved. The --~
reaction is allowed to proceed for 1/2 hour at room temperature while stirring. After a short rinse of the sample in deionized water, it is immersed in a 0.5 wt%
glutaraldehydelO.lM borate solution, pH=9.0, for 1/2 hour at room temperature while stirring. Subse~uently, the sample is rinsed thoroughly in deionized water, followed by placing the sample in a 1 wt% polyethyleneimine/O.lM borate solution (pH=9.0) for 1/4 hour at room temperature while stirring.
The amine-functionalization of the sample is followed by a treatment in 0.2M acetate buffered solution, pH=4.6, containing O.lM sodium cyanoborohydride to stabilize the surface by reduction of imine linkages and any free aldehyde groups. ~
Fib;ronectin is then immobilized onto the amine-functionalized substrate surface by reacting the fibronectin molecule with a carbodiimide to effect an activation of the carboxyl groups of the fibronectin molecule and reacting the :-: . ~ '' ' : . '.': `, '~ ' ~. :

-P-5076 12 2 1 1 2 6 ~ ~

carbodi mide-activated fibronectin molecule with the amine-functionalized substrate surface. The amine-functionalized substrate is inserted into a 0.5M MES buffered solution, pH=5.0, containing 0.22 mg/ml lyophilisate (4.556 wt%
fibronectin) and EDC is added to this solution until a final concentration of O.lM is achieved. The reaction is performed at 0-4C for 3 hours while stirring. The test sample is then copiously rinsed with deionized water, lM
NaCl, lM NaHC03, and again deionized water. The restoration - of carboxyl groups can then be accomplished by mild hydrolysis. The sample with fibronectin molecules is incubated in a lM NaHC03 solution, pH=8.2, for 8 hours at 37C.

Fibronectin was attached to an acrylamide-grafted substrate according to the present invention using the following method.
A hydrolyzed acrylamide-grafted test sample is inserted into a 0.1 wt% polyethyleneimine solution with the pH
adjusted to pH=4. To this solution, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide is added until a final concentration of O.OlM is achieved. The reaction is allowed to continue for 1/2 hour at room temperature while stirring. Fibronectin is then immobilized onto the test sample as set forth in Example 3.
It will be appreciated by those skilled in the art that while the invention has been described above in connection with particular embodiments and examples, the invention is not necessarily so limited and that numerous other embodiments, examples, uses, modifications and departures from thé embodiments, examples and uses may be made without departing from the inventive concepts.

.: ' ~ . .

Claims (14)

1. A method for attaching a biomolecule having a plurality of carboxyl groups to an aminated solid surface comprising the steps of:
(a) reacting the biomolecule with a carbodiimide to effect an activation with the carboxyl groups of the biomolecule;
(b) reacting the carbodiimide activated biomolecule with the solid surface to covalently bind the biomolecule to the aminated solid surface; and (c) selectively restoring carboxyl group functionality lost during step (a) to the biomolecule.
2. The method of claim 1 wherein the selective restoration of carboxyl group functionality is accomplished by mild hydrolysis.
3. A method for attaching a biomolecule having carboxyl groups to an aminated solid surface comprising the steps of:
(a) reacting the biomolecule with a carbodiimide to effect an activation of the carboxyl groups of the biomolecule;
(b) reacting the carbodiimide activated biomolecule to the aminated solid surface to covalently bind the biomolecule to the aminated solid surface; and (c) removing N-acyl urea groups from the covalently bound biomolecule.
4. The method of claim 1 wherein the removal of N-acyl urea groups is accomplished by mild hydrolysis.
5. The method of claim 1 or 3 wherein the aminated solid surface comprises a polymer having functional amine groups grafted to a solid substrate.
6. The method of claim 5 wherein the granted polymer is an acrylamide polymer functionalized with amine groups.
7. The method of claim 5 wherein the solid substrate is a polymeric substrate selected from the group consisting of polyurethane, silicone elastomer, polyolefins, fluoropolymers, polyesters, and polyacrylates.
8. The method of claim 1 or 3 wherein the biomolecule is selected from the group consisting of growth factors, antimicrobial agents, antithrombogenic agents, and cell attachment proteins.
9. The method of claim 8 wherein the biomolecule is heparin.
10. The method of claim 8 wherein the biomolecule is fibronectin.
11. The method of claim 1 or 3 wherein the carbodiimide has the structure R1N=C=NR2 where R1 is an alkyl or cycloalkyl group and R2 is an alkylamine or cycloalkylamine group.
12. The method of claim 11 wherein the carbodiimide is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
13. The method of claim 2 or 4 wherein the mild hydrolysis is carried out at a temperature in the range of about 0°C to 70°C.
14. The method of claim 2 or 4 wherein the mild hydrolysis is carried out at a pH in the range of about 8 to 11.
CA002112619A 1993-01-19 1993-12-30 Method for improving the biocompatibility of solid surfaces Abandoned CA2112619A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/005,711 1993-01-19
US08/005,711 US5350800A (en) 1993-01-19 1993-01-19 Method for improving the biocompatibility of solid surfaces

Publications (1)

Publication Number Publication Date
CA2112619A1 true CA2112619A1 (en) 1994-07-20

Family

ID=21717311

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002112619A Abandoned CA2112619A1 (en) 1993-01-19 1993-12-30 Method for improving the biocompatibility of solid surfaces

Country Status (6)

Country Link
US (1) US5350800A (en)
EP (1) EP0608095B1 (en)
JP (1) JP3529821B2 (en)
AU (1) AU670143B2 (en)
CA (1) CA2112619A1 (en)
DE (1) DE69418220T2 (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876454A (en) * 1993-05-10 1999-03-02 Universite De Montreal Modified implant with bioactive conjugates on its surface for improved integration
US5824651A (en) * 1993-05-10 1998-10-20 Universite De Montreal Process for modification of implant surface with bioactive conjugates for improved integration
JP3708567B2 (en) * 1994-07-20 2005-10-19 日清紡績株式会社 Method for immobilizing biologically active substances
US6179817B1 (en) 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5869127A (en) * 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US5679659A (en) * 1995-08-22 1997-10-21 Medtronic, Inc. Method for making heparinized biomaterials
US5767108A (en) * 1995-08-22 1998-06-16 Medtronic, Inc. Method for making improved heparinized biomaterials
US5672638A (en) * 1995-08-22 1997-09-30 Medtronic, Inc. Biocompatability for solid surfaces
CA2197375C (en) * 1996-02-15 2003-05-06 Yasuhiro Okuda Artificial blood vessel
IL117934A0 (en) * 1996-04-16 1996-08-04 Yeda Res & Dev Continuous production of allicin
US5674236A (en) * 1996-04-30 1997-10-07 Medtronic, Inc. Lancet for capillary puncture blood samples
US5811151A (en) * 1996-05-31 1998-09-22 Medtronic, Inc. Method of modifying the surface of a medical device
US5728751A (en) * 1996-11-25 1998-03-17 Meadox Medicals, Inc. Bonding bio-active materials to substrate surfaces
US5891196A (en) * 1997-04-16 1999-04-06 Baxter International Inc. Method for actively binding heparin to crosslinked biological tissues
US5760130A (en) * 1997-05-13 1998-06-02 Molecular Dynamics, Inc. Aminosilane/carbodiimide coupling of DNA to glass substrate
US6197289B1 (en) 1997-07-01 2001-03-06 Terumo Cardiovascular Systems Corporation Removal of biologically active agents
US6146771A (en) * 1997-07-01 2000-11-14 Terumo Cardiovascular Systems Corporation Process for modifying surfaces using the reaction product of a water-insoluble polymer and a polyalkylene imine
US20050171478A1 (en) * 1998-01-13 2005-08-04 Selmon Matthew R. Catheter system for crossing total occlusions in vasculature
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US6024918A (en) * 1998-03-13 2000-02-15 Medtronic, Inc. Method for attachment of biomolecules to surfaces of medical devices
US20070087028A1 (en) * 1998-04-16 2007-04-19 Robert Falotico Intraluminal devices for the prevention and treatment of vascular disease
US6087415A (en) * 1998-06-11 2000-07-11 Johnson & Johnson Vision Care, Inc. Biomedical devices with hydrophilic coatings
US6500481B1 (en) 1998-06-11 2002-12-31 Johnson & Johnson Vision Care, Inc. Biomedical devices with amid-containing coatings
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
WO2000041739A1 (en) * 1999-01-15 2000-07-20 University Of Utah Research Foundation Attachment of acid moiety-containing biomolecules to activated polymeric surfaces
US6478423B1 (en) 1999-10-12 2002-11-12 Johnson & Johnson Vison Care, Inc. Contact lens coating selection and manufacturing process
US7220276B1 (en) * 2000-03-06 2007-05-22 Surmodics, Inc. Endovascular graft coatings
US20020076835A1 (en) * 2000-07-14 2002-06-20 Ede Nicholas Jon Modular grafted polymeric surfaces
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020111590A1 (en) 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20070276476A1 (en) * 2000-09-29 2007-11-29 Llanos Gerard H Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon
CA2424029C (en) 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
US20040213827A1 (en) * 2000-12-21 2004-10-28 Enns John B. Antimicrobial contact lenses and methods for their production
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US6656216B1 (en) 2001-06-29 2003-12-02 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
GB0122393D0 (en) * 2001-09-17 2001-11-07 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility
US20030065377A1 (en) 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
DK1435877T3 (en) 2001-10-15 2009-08-03 Hemoteq Ag Coating of stents to prevent restenosis
US7173073B2 (en) * 2002-01-14 2007-02-06 Johnson & Johnson Vision Care, Inc. Ophthalmic devices containing heterocyclic compounds and methods for their production
US20030204168A1 (en) 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
US7169178B1 (en) 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US20040167572A1 (en) * 2003-02-20 2004-08-26 Roth Noah M. Coated medical devices
US7527632B2 (en) * 2003-03-31 2009-05-05 Cordis Corporation Modified delivery device for coated medical devices
US7629000B2 (en) 2003-05-13 2009-12-08 E.I. Du Pont De Nemours And Company Method for making antimicrobial polyester-containing articles with improved wash durability and articles made thereby
US20040236416A1 (en) * 2003-05-20 2004-11-25 Robert Falotico Increased biocompatibility of implantable medical devices
US20050033417A1 (en) * 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US20050137677A1 (en) 2003-12-17 2005-06-23 Rush Scott L. Endovascular graft with differentiable porosity along its length
US20050249776A1 (en) * 2003-12-19 2005-11-10 Chen Chao C Coated aneurysmal repair device
US8652502B2 (en) * 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
US8747881B2 (en) 2003-12-19 2014-06-10 Cordis Corporation Intraluminal medical devices in combination with therapeutic agents
KR100580642B1 (en) * 2004-01-12 2006-05-16 삼성전자주식회사 A method for immobilizing a biomolecule to a solid substrate at a high density by using a substrate having an activated carboxyl group at the surface thereof and microarray produced using the same
US7303758B2 (en) 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
US7806924B2 (en) * 2004-02-18 2010-10-05 Cordis Corporation Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis
US20050187608A1 (en) * 2004-02-24 2005-08-25 O'hara Michael D. Radioprotective compound coating for medical devices
US8828416B2 (en) 2004-03-09 2014-09-09 Cordis Corporation Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
US7695731B2 (en) 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
US7875282B2 (en) * 2004-03-22 2011-01-25 Cordis Corporation Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury
EP1732619A1 (en) * 2004-03-26 2006-12-20 SurModics, Inc. Composition and method for preparing biocompatible surfaces
CA2559741A1 (en) * 2004-03-26 2005-10-20 Surmodics, Inc. A medical article having a bioactive agent-releasing component with photoreactive groups
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US8007737B2 (en) 2004-04-14 2011-08-30 Wyeth Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US20060039950A1 (en) * 2004-08-23 2006-02-23 Zhengrong Zhou Multi-functional biocompatible coatings for intravascular devices
US20060129225A1 (en) * 2004-12-15 2006-06-15 Kopia Gregory A Device for the delivery of a cardioprotective agent to ischemic reperfused myocardium
WO2007005758A2 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Methods , compositions and devices for promoting angiogenesis
US20070026042A1 (en) * 2005-07-29 2007-02-01 Narayanan Pallasssana V System for treating aneurysmal disease
US20070048350A1 (en) * 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
US8784860B2 (en) * 2005-10-27 2014-07-22 Cordis Corporation Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease
US20070173787A1 (en) * 2005-11-01 2007-07-26 Huang Mark C T Thin-film nitinol based drug eluting stent
US20070116736A1 (en) * 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
US8069814B2 (en) 2006-05-04 2011-12-06 Advanced Cardiovascular Systems, Inc. Stent support devices
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US20090226495A1 (en) * 2007-07-17 2009-09-10 Picardi Salvatore Charles Nanodiamond enhanced efficacy
US8506984B2 (en) * 2006-07-26 2013-08-13 Cordis Corporation Therapeutic agent elution control process
US20080241215A1 (en) 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US20090074831A1 (en) * 2007-09-18 2009-03-19 Robert Falotico LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
US9603980B2 (en) 2008-02-26 2017-03-28 CARDINAL HEALTH SWITZERLAND 515 GmbH Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
KR102139022B1 (en) 2010-07-30 2020-07-29 알콘 인코포레이티드 A silicone hydrogel lens with a crosslinked hydrophilic coating
CA2840611A1 (en) 2011-06-30 2013-01-03 Dsm Ip Assets B.V. Silicone-containing monomer
HUE029018T2 (en) 2011-10-12 2017-02-28 Novartis Ag Method for making uv-absorbing ophthalmic lenses by coating
WO2014095690A1 (en) 2012-12-17 2014-06-26 Novartis Ag Method for making improved uv-absorbing ophthalmic lenses
US9757330B2 (en) 2013-10-18 2017-09-12 Industrial Technology Research Institute Recipe for in-situ gel, and implant, drug delivery system formed thereby
US9708087B2 (en) 2013-12-17 2017-07-18 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
CN106715101B (en) 2014-08-26 2019-11-05 诺华股份有限公司 Method for applying stable coating in silicone hydrogel contact lens on piece
EP3391101B1 (en) 2015-12-15 2020-07-08 Alcon Inc. Method for applying stable coating on silicone hydrogel contact lenses
CN111386478B (en) 2017-12-13 2023-11-14 爱尔康公司 Zhou Pao and month polishing gradient contact lens
CN115322429B (en) * 2022-08-24 2023-07-14 天津大学温州安全(应急)研究院 High anticoagulation extracorporeal circulation pipeline

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826678A (en) * 1972-06-06 1974-07-30 Atomic Energy Commission Method for preparation of biocompatible and biofunctional materials and product thereof
SE456347B (en) * 1982-02-09 1988-09-26 Ird Biomaterial Ab SURFACE MODIFIED SOLID SUBSTRATE AND PROCEDURES FOR PRODUCING THEREOF
US5217492A (en) * 1982-09-29 1993-06-08 Bio-Metric Systems, Inc. Biomolecule attachment to hydrophobic surfaces
US4521564A (en) * 1984-02-10 1985-06-04 Warner-Lambert Company Covalent bonded antithrombogenic polyurethane material
US5263992A (en) * 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
NL8701337A (en) * 1987-06-09 1989-01-02 Sentron V O F SUBSTRATE PROVIDED WITH A BLOOD COMPATIBLE SURFACE OBTAINED BY COUPLING WITH THE SURFACE OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE WITH AN INHIBITORY INFLUENCE ON THE FORMATION OF BLOOD CLOTS AND / OR CONTAINED FROM HARMFOLIC CIRCULARS.
US5055316A (en) * 1988-04-20 1991-10-08 Washington Research Foundation Tight binding of proteins to surfaces
US5167960A (en) * 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
US5053048A (en) * 1988-09-22 1991-10-01 Cordis Corporation Thromboresistant coating
US5080924A (en) * 1989-04-24 1992-01-14 Drexel University Method of making biocompatible, surface modified materials
NL194941C (en) * 1990-02-15 2003-08-04 Cordis Corp Method for applying a physiologically active compound to a substrate surface.
US5132108A (en) * 1990-11-08 1992-07-21 Cordis Corporation Radiofrequency plasma treated polymeric surfaces having immobilized anti-thrombogenic agents
US5229172A (en) * 1993-01-19 1993-07-20 Medtronic, Inc. Modification of polymeric surface by graft polymerization

Also Published As

Publication number Publication date
US5350800A (en) 1994-09-27
DE69418220T2 (en) 1999-12-30
EP0608095A1 (en) 1994-07-27
JPH08191887A (en) 1996-07-30
DE69418220D1 (en) 1999-06-10
JP3529821B2 (en) 2004-05-24
AU5237193A (en) 1994-07-28
AU670143B2 (en) 1996-07-04
EP0608095B1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
US5350800A (en) Method for improving the biocompatibility of solid surfaces
US5308641A (en) Biocompatibility of solid surfaces
US5821343A (en) Oxidative method for attachment of biomolecules to surfaces of medical devices
US7122356B2 (en) Method for attachment of biomolecules to medical device surfaces
US6143354A (en) One-step method for attachment of biomolecules to substrate surfaces
US5928916A (en) Ionic attachment of biomolecules with a guanidino moiety to medical device surfaces
US6303179B1 (en) Method for attachment of biomolecules to surfaces through amine-functional groups
US5811151A (en) Method of modifying the surface of a medical device
EP0826382B1 (en) Biomolecule attachment
US5607475A (en) Biocompatible medical article and method
US5945319A (en) Periodate oxidative method for attachment of biomolecules to medical device surfaces
DE69822872T2 (en) METHOD FOR THE OXIDATIVE BINDING OF GLYCOPROTEINS AND GLYCOPEPTIDES TO SURFACES OF MEDICAL ARTICLES
US5767108A (en) Method for making improved heparinized biomaterials
EP0930900B1 (en) Biocompatibility for solid surfaces
AU714265B2 (en) Biocompatible medical article and method
EP0480843A2 (en) Antithrombogenic medical material and medical device

Legal Events

Date Code Title Description
FZDE Discontinued